# Safety and Tolerability of TG1050: A Dose-finding Study

> **NCT02428400** · PHASE1 · COMPLETED · sponsor: **Transgene** · enrollment: 48 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** TG1050
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02428400
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428400, "Safety and Tolerability of TG1050: A Dose-finding Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02428400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*